BIO · Bio-Rad Laboratories, Inc. · Executive Compensation

$379.02 +10.47 (+2.84%)

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$9.88B

26.74M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	Chief Executive Officer and Chairman	$1,089,877	—	$4,856,574	$1,458,975	$562,088	$28,327	$7,995,841
Jonathan DiVincenzo	COO	$673,208	—	$2,023,696	$484,122	$476,702	$23,044	$3,680,772
Jonathan P. DiVincenzo	President and Chief Operating Officer	$673,208	—	$2,023,696	$484,122	$476,702	$23,044	$3,680,772
Roop K. Lakkaraju	Executive Vice President, Chief Financial Officer	$629,100	—	$1,618,956	$387,358	$334,212	$21,112	$2,990,738
Roop Lakkaraju	CFO	$629,100	—	$1,618,956	$387,358	$334,212	$21,112	$2,990,738
Rajat Mehta	Executive Vice President, Global Commercial Operations	$220,096	—	$2,158,707	—	$270,106	$31,133	$2,680,042
James Barry	Executive Vice President, President, Life Science Group	$536,752	—	$1,214,217	$290,493	$266,079	$303,685	$2,611,227

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	Chief Executive Officer and Chairman	$1,059,500	—	$4,557,805	$2,280,086	$364,003	$28,077	$8,289,471
Jonathan P. DiVincenzo	President and Chief Operating Officer	$204,515	$1,300,000	$2,453,382	—	$56,928	$299,260	$4,314,185
Jonathan DiVincenzo	COO	$204,515	$1,300,000	$2,453,382	—	$56,928	$299,260	$4,314,185
Roop Lakkaraju	CFO	$426,923	—	$3,225,018	—	$88,197	$34,937	$3,775,075
Roop K. Lakkaraju	Executive Vice President, Chief Financial Officer	$426,923	—	$3,225,018	—	$88,197	$34,937	$3,775,075

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	President, Chief Executive Officer and Chairman	$1,040,000	—	$6,211,537	—	—	$212,341	$7,463,878
Andrew Last	Executive Vice President Chief Operating Officer	$660,250	—	$2,587,795	—	—	$22,044	$3,270,089
Ilan Daskal	Former Executive Vice President and Chief Financial Officer	$565,093	—	$2,070,766	—	—	$20,112	$2,655,971
Dara Grantham Wright	Executive Vice President, President, Clinical Diagnostics Group	$562,390	—	$1,552,976	—	—	$17,760	$2,133,126
Simon May	Executive Vice President, President, Life Science Group	$517,813	—	$1,552,976	—	—	$18,432	$2,089,221

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	President, Chief Executive Officer and Chairman	$1,030,154	—	$5,398,348	—	$1,073,406	$26,077	$7,527,985
Andrew Last	Executive Vice President Chief Operating Officer	$638,566	—	$2,249,393	—	$457,382	$20,794	$3,366,135
Ilan Daskal	Former Executive Vice President and Chief Financial Officer	$580,241	—	$1,800,098	—	$353,331	$18,862	$2,752,532
Dara Grantham Wright	Executive Vice President, President, Clinical Diagnostics Group	$539,915	—	$1,349,830	—	$293,483	$16,130	$2,199,358
Simon May	Executive Vice President, President, Life Science Group	$499,737	—	$1,349,830	—	$270,845	$17,182	$2,137,594

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	President, Chief Executive Officer and Chairman	$987,885	—	$4,126,907	$1,423,476	$2,132,330	$25,327	$8,695,925
Andrew Last	Executive Vice President Chief Operating Officer	$610,760	—	$2,063,453	$603,703	$913,453	$20,044	$4,211,413
Ilan Daskal	Former Executive Vice President and Chief Financial Officer	$526,706	—	$1,485,654	$434,657	$639,314	$18,112	$3,104,443
Dara Grantham Wright	Executive Vice President, President, Clinical Diagnostics Group	$516,101	—	$1,321,034	$386,494	$531,576	$15,380	$2,770,585
Michael Crowley	Executive Vice President, President, Global Commercial Operations The amounts reported under “Stock Awards” and “Option Awards” in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in Note 9 to the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 and filed with the Securities and Exchange Commission. Please see the “Grants of Plan-Based Awards Table” for more information regarding equity awards granted during fiscal year 2021. “Non-Equity Incentive Plan Compensation” is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2019, 2020 and 2021 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled “Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program).” Amounts earned in 2019 were paid during fiscal year 2020, amounts earned in 2020 were paid during fiscal year 2021 and amounts earned in 2021 were paid in fiscal year 2022. “All Other Compensation” for 2021 represents: contributions to each named executive officer of 14,250 to our tax qualified profit sharing plan; and term life insurance costs paid on behalf of the named executive officers. In addition, for Ms. Grantham Wright “All Other Compensation” for 2020 also includes 156,921 for reimbursement of moving expenses in connection with her commencement of employment with us. Ms. Grantham Wright became a named executive officer for the first time for the fiscal year ended December 31, 2020. Mr. Crowley was a named executive officer in 2019 and 2021.	$470,456	—	$1,321,034	$386,494	$483,186	$21,296	$2,682,466

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	President, Chief Executive Officer and Chairman	$986,538	—	$3,785,446	$1,193,773	$2,000,094	$26,572	$7,992,423
Andrew Last	Executive Vice President Chief Operating Officer	$612,346	—	$1,892,723	$532,987	$871,437	$14,659	$3,924,152
Ilan Daskal	Executive Vice President and Chief Financial Officer	$530,654	—	$1,135,634	$319,792	$612,844	$11,506	$2,610,430
Dara Grantham Wright	Executive Vice President, President, Clinical Diagnostics Group Simon May ^^ Executive Vice President, President, Life Science Group	$519,231	$200,000	$908,612	$255,863	$503,456	$164,498	$2,551,660
Annette Tumolo	Executive Vice President, President, Life Science Group The amounts reported under “Stock Awards” and “Option Awards” in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in Note 9 to the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 and filed with the Securities and Exchange Commission. Please see the “Grants of Plan-Based Awards Table” for more information regarding equity awards granted during fiscal year 2020. “Non-Equity Incentive Plan Compensation” is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2018, 2019 and 2020 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled “Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program).” Amounts earned in 2018 were paid during fiscal year 2019, amounts earned in 2019 were paid during fiscal year 2020 and amounts earned in 2020 were paid in fiscal year 2021. “All Other Compensation” for 2020 represents: contributions to each of Mr. Schwartz and Ms. Tumolo of 14,250 to our tax qualified profit sharing plan, and the other named executive officers received contributions in the following amounts, based on their respective hire dates in 2019 and the applicable eligibility waiting period: Mr. Daskal: 7,894; Dr. Last: 9,115; and Ms. Grantham Wright: 6,731; and term life insurance costs paid on behalf of the named executive officers. In addition, for Ms. Grantham Wright “All Other Compensation” for 2020 also includes 156,921 for reimbursement of moving expenses in connection with her commencement of employment with us. Mr. Daskal and Dr. Last each became a named executive officer for the first time for the fiscal year ended December 31, 2019. Represents a sign-on bonus paid to Dr. Last in connection with his commencement of employment with us. Ms. Grantham Wright became a named executive officer for the first time for the fiscal year ended December 31, 2020. Represents a sign-on bonus paid to Ms. Grantham Wright in connection with her commencement of employment with us.	$518,635	—	$908,612	$255,863	$508,491	$24,918	$2,216,519
Michael Crowley	Executive Vice President, President, Global Commercial Operations The amounts reported under “Stock Awards” and “Option Awards” in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in Note 9 to the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 and filed with the Securities and Exchange Commission. Please see the “Grants of Plan-Based Awards Table” for more information regarding equity awards granted during fiscal year 2021. “Non-Equity Incentive Plan Compensation” is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2019, 2020 and 2021 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled “Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program).” Amounts earned in 2019 were paid during fiscal year 2020, amounts earned in 2020 were paid during fiscal year 2021 and amounts earned in 2021 were paid in fiscal year 2022. “All Other Compensation” for 2021 represents: contributions to each named executive officer of 14,250 to our tax qualified profit sharing plan; and term life insurance costs paid on behalf of the named executive officers. In addition, for Ms. Grantham Wright “All Other Compensation” for 2020 also includes 156,921 for reimbursement of moving expenses in connection with her commencement of employment with us. Ms. Grantham Wright became a named executive officer for the first time for the fiscal year ended December 31, 2020. Mr. Crowley was a named executive officer in 2019 and 2021.	$473,580	—	$908,612	$255,863	$463,180	$14,664	$2,115,899

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	President, Chief Executive Officer and Chairman	$950,000	—	$3,865,744	$1,277,192	$1,143,383	$24,734	$7,261,053
Andrew Last	Executive Vice President Chief Operating Officer	$387,019	$50,000	$1,496,200	$412,894	$335,023	$53,625	$2,734,761
Ilan Daskal	Executive Vice President and Chief Financial Officer	$365,385	—	$1,084,440	$299,263	$256,259	$1,412	$2,006,759
Annette Tumolo	Executive Vice President, President, Life Science Group The amounts reported under “Stock Awards” and “Option Awards” in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in Note 9 to the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 and filed with the Securities and Exchange Commission. Please see the “Grants of Plan-Based Awards Table” for more information regarding equity awards granted during fiscal year 2020. “Non-Equity Incentive Plan Compensation” is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2018, 2019 and 2020 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled “Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program).” Amounts earned in 2018 were paid during fiscal year 2019, amounts earned in 2019 were paid during fiscal year 2020 and amounts earned in 2020 were paid in fiscal year 2021. “All Other Compensation” for 2020 represents: contributions to each of Mr. Schwartz and Ms. Tumolo of 14,250 to our tax qualified profit sharing plan, and the other named executive officers received contributions in the following amounts, based on their respective hire dates in 2019 and the applicable eligibility waiting period: Mr. Daskal: 7,894; Dr. Last: 9,115; and Ms. Grantham Wright: 6,731; and term life insurance costs paid on behalf of the named executive officers. In addition, for Ms. Grantham Wright “All Other Compensation” for 2020 also includes 156,921 for reimbursement of moving expenses in connection with her commencement of employment with us. Mr. Daskal and Dr. Last each became a named executive officer for the first time for the fiscal year ended December 31, 2019. Represents a sign-on bonus paid to Dr. Last in connection with his commencement of employment with us. Ms. Grantham Wright became a named executive officer for the first time for the fiscal year ended December 31, 2020. Represents a sign-on bonus paid to Ms. Grantham Wright in connection with her commencement of employment with us.	$480,304	—	$928,019	$235,208	$270,062	$19,544	$1,933,137
Michael Crowley	Executive Vice President, President, Global Commercial Operations The amounts reported under “Stock Awards” and “Option Awards” in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in Note 9 to the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 and filed with the Securities and Exchange Commission. Please see the “Grants of Plan-Based Awards Table” for more information regarding equity awards granted during fiscal year 2021. “Non-Equity Incentive Plan Compensation” is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2019, 2020 and 2021 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled “Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program).” Amounts earned in 2019 were paid during fiscal year 2020, amounts earned in 2020 were paid during fiscal year 2021 and amounts earned in 2021 were paid in fiscal year 2022. “All Other Compensation” for 2021 represents: contributions to each named executive officer of 14,250 to our tax qualified profit sharing plan; and term life insurance costs paid on behalf of the named executive officers. In addition, for Ms. Grantham Wright “All Other Compensation” for 2020 also includes 156,921 for reimbursement of moving expenses in connection with her commencement of employment with us. Ms. Grantham Wright became a named executive officer for the first time for the fiscal year ended December 31, 2020. Mr. Crowley was a named executive officer in 2019 and 2021.	$441,663	—	$928,019	$235,208	$203,229	$18,174	$1,826,293
Christine A. Tsingos	Former Executive Vice President and Chief Financial Officer	$200,688	—	—	—	$89,836	$14,730	$305,234

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	President, Chief Executive Officer and Chairman	$942,468	—	$4,239,950	$1,711,111	$490,200	$255,685	$7,639,414
Annette Tumolo	Executive Vice President, President, Life Science Group The amounts reported under “Stock Awards” and “Option Awards” in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation – Stock Compensation. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in Note 9 to the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 and filed with the Securities and Exchange Commission. Please see the “Grants of Plan-Based Awards Table” for more information regarding equity awards granted during fiscal year 2020. “Non-Equity Incentive Plan Compensation” is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2018, 2019 and 2020 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled “Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program).” Amounts earned in 2018 were paid during fiscal year 2019, amounts earned in 2019 were paid during fiscal year 2020 and amounts earned in 2020 were paid in fiscal year 2021. “All Other Compensation” for 2020 represents: contributions to each of Mr. Schwartz and Ms. Tumolo of 14,250 to our tax qualified profit sharing plan, and the other named executive officers received contributions in the following amounts, based on their respective hire dates in 2019 and the applicable eligibility waiting period: Mr. Daskal: 7,894; Dr. Last: 9,115; and Ms. Grantham Wright: 6,731; and term life insurance costs paid on behalf of the named executive officers. In addition, for Ms. Grantham Wright “All Other Compensation” for 2020 also includes 156,921 for reimbursement of moving expenses in connection with her commencement of employment with us. Mr. Daskal and Dr. Last each became a named executive officer for the first time for the fiscal year ended December 31, 2019. Represents a sign-on bonus paid to Dr. Last in connection with his commencement of employment with us. Ms. Grantham Wright became a named executive officer for the first time for the fiscal year ended December 31, 2020. Represents a sign-on bonus paid to Ms. Grantham Wright in connection with her commencement of employment with us.	$462,811	—	$978,450	$267,746	$133,386	$19,294	$1,861,687
Christine A. Tsingos	Former Executive Vice President and Chief Financial Officer	$438,150	—	$978,450	$267,746	$124,347	$19,234	$1,827,927
Michael Crowley	Executive Vice President, Global Commercial Operations	$427,724	—	$978,450	$267,746	$122,658	$17,924	$1,814,502

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Norman Schwartz	President, Chief Executive Officer and Chairman	$922,022	—	$2,807,740	$1,012,928	$637,818	$24,168	$5,404,676
Christine A. Tsingos	Former Executive Vice President and Chief Financial Officer	$438,150	—	$647,940	$151,691	$151,547	$17,674	$1,407,002
Michael Crowley	Executive Vice President, Global Commercial Operations	$415,575	—	$647,940	$151,691	$158,113	$19,242	$1,392,561

Executive changes

Person	Role	Change	Effective	Filed
Rajat Mehta	Executive Vice President, Global Commercial Operations	Appointed	2025-08-04	2025-07-28
Michael Crowley	Executive Vice President, Global Commercial Operations	Retired	2025-08-04	2025-07-28
Andrew Last	Executive Vice President, Chief Operating Officer (and principal operating officer)	Retired	2024-09-05	2024-08-20
Jonathan P. DiVincenzo	President and Chief Operating Officer (including as principal operating officer)	Appointed	2024-09-09	2024-08-20
James J. Barry	Executive Vice President and President, Life Science Group	Appointed	2024-05-01	2024-04-26
Roop K. Lakkaraju	principal accounting officer	Appointed	2024-04-26	2024-04-26
Simon May	Executive Vice President and President, Life Science Group	Resigned	2024-05-01	2024-04-26
Roop K. Lakkaraju	Executive Vice President, Chief Financial Officer	Appointed	2024-04-15	2024-03-20

Key facts CIK 12208 CUSIP 090572207 13F (30d) 18 filings 17 filers Visit website Investor relations